Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation | Zendy

Hengwei Wu | Zendy; Jimin Shi | Zendy; Yi Luo | Zendy; Yamin Tan | Zendy; Mingming Zhang | Zendy; Xiaoyu Lai | Zendy; Jian Yu | Zendy; Lizhen Liu | Zendy; Huarui Fu | Zendy; He Huang | Zendy; Yanmin Zhao | Zendy

Open Access

Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Author(s) -

Hengwei Wu,

Jimin Shi,

Yi Luo,

Yamin Tan,

Mingming Zhang,

Xiaoyu Lai,

Jian Yu,

Lizhen Liu,

Huarui Fu,

He Huang,

Yanmin Zhao

Publication year - 2021

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2020.34750

Subject(s) - ruxolitinib , graft versus host disease , hematopoietic stem cell transplantation , host (biology) , haematopoiesis , stem cell , transplantation , medicine , refractory (planetary science) , immunology , hematopoietic stem cell , cancer research , oncology , biology , myelofibrosis , microbiology and biotechnology , bone marrow , genetics , astrobiology

Key Points Question Is ruxolitinib an option for patients with steroid-refractory chronic graft-vs-host disease, and what characteristics are associated with treatment response? Findings In this case series of 41 patients with steroid-refractory chronic graft-vs-host disease who were treated with ruxolitinib, heavily pretreated patients could achieve meaningful responses with a favorable safety profile. No lung involvement and haploidentical donors were associated with response to ruxolitinib. Meaning In this study, monotherapy with ruxolitinib was associated with a meaningful response in patients with steroid-refractory chronic graft-vs-host disease, suggesting a possible therapeutic option for a serious disease with no currently accepted standard-of-care treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research